D. Dearnaley

发表

Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done?

D. Dearnaley, V. Khoo, N. Van As, 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

Intensity modulated radiation therapy: a clinical review.

D P Dearnaley, S Webb, S. Webb, 2000, The British journal of radiology.

Cardiovascular disease as a long-term complication of treatment for testicular cancer.

D P Dearnaley, D. Dearnaley, A. Horwich, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The activity of single-agent carboplatin in advanced seminoma.

A. Horwich, R. A’Hern, J. Nicholls, 1992, European journal of cancer.

Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis.

D. Dearnaley, A. Horwich, C. Fisher, 1994, The Journal of urology.

Simple nontoxic treatment of advanced metastatic seminoma with carboplatin.

M. Williams, A. Horwich, M. Brada, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity

D. Dearnaley, V. Khoo, S. Hassan, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy.

D P Dearnaley, S Webb, J L Bedford, 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer.

D. Dearnaley, V. Khoo, A. Norman, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study.

D. Dearnaley, K. Harrington, C. Clark, 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Current opinion on adjuvant and salvage treatment after radical prostatectomy.

A. Horwich, R. Huddart, D. Dearnaley, 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

Residual mass following chemotherapy of seminoma.

D. Dearnaley, A. Horwich, R. Huddart, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

IMRT clinical implementation: Prostate and pelvic node irradiation using Helios and a 120‐leaf multileaf collimator

D. Dearnaley, C. Clark, J. Staffurth, 2002, Journal of applied clinical medical physics.

Hypofractionated radiotherapy for patients with carcinoma of the bladder.

D. Dearnaley, A. Horwich, R. Huddart, 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).

How patients manage gastrointestinal symptoms after pelvic radiotherapy

D. Dearnaley, K. Harrington, A. Norman, 2003, Alimentary pharmacology & therapeutics.

Radiogenomics A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity

M. Sydes, A. Dunning, K. Michailidou, 2022 .

Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.

A. Horwich, A. Norman, D. Dearnaley, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy.

S. Webb, D. Dearnaley, C. Nutting, 2002, The British journal of radiology.

Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.

D. Dearnaley, V. Khoo, C. Clark, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397.

Steve Webb, Philip M Evans, Mike Partridge, 2010, International journal of radiation oncology, biology, physics.

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.

M. Parmar, M. Sydes, D. Dearnaley, 2014, The Lancet. Oncology.

Reduced dose posterior to prostate correlates with increased PSA progression in voxel-based analysis of 3 randomised phase 3 trials.

M. Sydes, D. Dearnaley, L. Holloway, 2020, International journal of radiation oncology, biology, physics.

Hand pattern indicates prostate cancer risk

R. Eeles, Z. Kote-Jarai, M. Guy, 2010, British Journal of Cancer.

Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist.

D. Dearnaley, H. Andreyev, A. Muls, 2014, The Lancet. Oncology.

Long-term outcome after percutaneous treatment of transitional cell carcinoma of the renal pelvis.

D. Dearnaley, C. Woodhouse, M. Kellett, 1996, The Journal of urology.

Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer.

D. Dearnaley, A. Horwich, R. Huddart, 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

The significance of rectal bleeding after pelvic radiotherapy

D. Dearnaley, D. Tait, P. Blake, 2005, Alimentary pharmacology & therapeutics.

Frequency of screening magnetic resonance imaging to detect occult spinal cord compromise and to prevent neurological deficit in metastatic castration-resistant prostate cancer.

A. Horwich, R. Huddart, R. Venkitaraman, 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

Whole‐body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer

R. Eeles, A. Horwich, V. Khoo, 2009, Journal of medical imaging and radiation oncology.

Current Issues in Cancer: Cancer of the prostate

D. Dearnaley, P. Meredith, J. Mullins, 1994 .